Idioma:

Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma

LEBLOND, Véronique ; JOHNSON, Steve ; DILHUYDY, Marie-Sarah ; WILLOUGHBY, Sara ; DARTIGEAS, Caroline ; MALPHETTES, Marion ; ROYER, Bruno ; EWINGS, Maeve ; PRATT, Guy ; LEJEUNE, Julie ; NGUYEN-KHAC, Florence ; CHOQUET, Sylvain ; CHEVRET, Sylvie ; OWEN, Roger G ; COPPLESTONE, Adrian ; RULE, Simon ; TOURNILHAC, Olivier ; FRANCIS SEYMOUR, John ; PATMORE, Russell D ; WRIGHT, David ; MOREL, Pierre

Journal of clinical oncology, 2013-01, Vol.31 (3), p.301-307 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por

Enviar para

Título:
Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma
Autor: LEBLOND, Véronique ; JOHNSON, Steve ; DILHUYDY, Marie-Sarah ; WILLOUGHBY, Sara ; DARTIGEAS, Caroline ; MALPHETTES, Marion ; ROYER, Bruno ; EWINGS, Maeve ; PRATT, Guy ; LEJEUNE, Julie ; NGUYEN-KHAC, Florence ; CHOQUET, Sylvain ; CHEVRET, Sylvie ; OWEN, Roger G ; COPPLESTONE, Adrian ; RULE, Simon ; TOURNILHAC, Olivier ; FRANCIS SEYMOUR, John ; PATMORE, Russell D ; WRIGHT, David ; MOREL, Pierre
Assuntos: Aged ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Chlorambucil - therapeutic use ; Disease-Free Survival ; Female ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Kaplan-Meier Estimate ; Lymphoma, B-Cell, Marginal Zone - drug therapy ; Lymphoma, B-Cell, Marginal Zone - mortality ; Male ; Medical sciences ; Middle Aged ; Proportional Hazards Models ; Tumors ; Vidarabine - analogs & derivatives ; Vidarabine - therapeutic use ; Waldenstrom Macroglobulinemia - drug therapy ; Waldenstrom Macroglobulinemia - mortality
É parte de: Journal of clinical oncology, 2013-01, Vol.31 (3), p.301-307
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
Descrição: Treatment options for patients with Waldenström macroglobulinemia (WM) and closely related disorders include alkylating agents, purine analogs, and monoclonal antibodies. No large randomized studies have yet been reported comparing any of these approaches. The randomized WM1 study (Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia) was undertaken in 101 centers in five countries enrolling 414 eligible patients (339 with WM, 37 with non-mucosa-associated lymphoid tissue marginal zone lymphoma, and 38 with lymphoplasmacytic lymphoma) who were randomly assigned to receive chlorambucil or fludarabine. The primary end point was the overall response rate (ORR). On the basis of intent-to-treat analysis, the ORR was 47.8% (95% CI, 40.9% to 54.8%) in the fludarabine arm versus 38.6% (95% CI, 32.0% to 45.7%) in the chlorambucil arm (P = .07). With a median follow-up of 36 months (interquartile range, 18 to 58 months), median progression-free survival (PFS), and duration of response (DR) were significantly improved in the fludarabine arm compared with the chlorambucil arm: PFS, 36.3 versus 27.1 months (P = .012) and DR, 38.3 versus 19.9 months (P < .001). In patients with WM, median overall survival (OS) was not reached in the fludarabine arm versus 69.8 months in the chlorambucil arm (95% CI, 61.6 to 79.8 months; P = .014). Grade 3 to 4 neutropenia was significantly higher among patients treated with fludarabine (36%) compared with patients treated with chlorambucil (17.8%; P < .001). Second malignancies were significantly more frequent in the chlorambucil arm with 6-year cumulative incidence rate of 20.6% versus 3.7% in the fludarabine arm (P = .001). In the complete intent-to-treat study population, fludarabine significantly improved PFS compared with chlorambucil, and in patients with WM, it improved OS.
Editor: Alexandria, VA: American Society of Clinical Oncology
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma

Alexandria, VA: American Society of Clinical Oncology

Buscando em bases de dados remotas. Favor aguardar.